论文部分内容阅读
为了检查参加实施地区结核病规程(DTP)卫生机构的短程化学治疗(SCC)病人的细菌学情况,以及耐药者所占比率,在North Arcot区和Pondicherry地区收集了治疗前后的痰村本。在North Arcot区,头2个月每个周给予利福平、异烟肼、和吡嗪酰胺各2次,其后4个月每周利福平和异烟肼各2次,在充分监督下服药。在Pondicherry,头2个月每日给予利福平、异烟肼和吡嗪酰胺,其后4个月每周利福平和异烟肼各2次。在接受了80％或以上药物的病人中,North Arcot有80％、Pondicherry有92％的病人于治疗结束时痰结核杆培养转为阴性。甚至在起初细菌耐药的病人中,相当大的一部分反应良好。在治疗开始前,North Arcot的2779名病人中,25％对一种或一种以上药物耐药,包括2％对利福平耐药者。在Pondicherry,13％的病人起初对一种或一种以上药物耐药。起初对利福平耐药者占0.9％。治疗结束时,原起初耐药者中无一例对利福平有获得性耐药。
To check the bacteriological status of TB patients attending DTP health facilities and the share of drug-resistant people, phlegm villages before and after treatment were collected in North Arcot and Pondicherry. In the North Arcot district, rifampicin, isoniazid, and pyrazinamide were given twice a week for the first 2 months and rifampicin and isoniazid were administered twice weekly for the next 4 months, with adequate supervision. In Pondicherry, rifampicin, isoniazid and pyrazinamide were administered daily for the first 2 months, followed by rifampicin and isoniazid twice weekly for the next 4 months. Among patients who received 80% or more of their medications, 80% of North Arcot and 92% of Pondicherry turned negative for sputum by the end of treatment. A substantial proportion of patients who initially developed bacterial resistance responded well. Before the start of treatment, 25% of 2779 patients in North Arcot were resistant to one or more drugs, including 2% of those resistant to rifampicin. In Pondicherry, 13% of patients initially developed resistance to one or more drugs. At first 0.9% were resistant to rifampicin. At the end of treatment, none of the original resistant patients had acquired resistance to rifampicin.